Request Your Free Trend Report Now:

"The Obesity Drug Revolution"

In this Trendline, we'll take an in depth look inside the booming weight loss drug market.

Known as GLP-1 agonists, new drugs could change how doctors treat obesity and, possibly, how the condition is more broadly understood. They could also raise healthcare spending substantially, posing a problem for insurers looking to control costs.

Included in this Trendline:

• Wegovy approval for the heart broadens obesity drug use
• Medicare cracks open coverage for Novo obesity drug
• Novo pill could be company’s next entrant in obesity drug race

Offered Free by: BioPharma Dive and OPEN Health
See All Resources from: BioPharma Dive and OPEN Health